



PASS — ALL SPECIFICATIONS MET

4 of 4 layers complete


■ L1  
Identity

■ L2  
Purity

■ L3  
Net Peptide Content

■ L4  
Sterility

Sample & Vial Validation



Vial A: as received & analyzed

|             |                     |                |                  |
|-------------|---------------------|----------------|------------------|
| Client      | AncientCity Biotech | Product        | NAD+             |
| Lot / Batch | 926-ND-500          | Label Claim    | 500 mg           |
| Matrix      | lyophilized powder  | Sample Count   | 1                |
| Vial Size   | 10mL                | Cap Color      | Royal Blue       |
| Crimp Color | Silver / Aluminum   | Contents Color | White            |
| Seal Intact | Yes                 | Condition      | sealed, intact   |
| Received    | Sep 2, 2026         | Sampling       | client submitted |

Test Results

| Test                  | Reference standard                                                                                                                                          | Result                              |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| Identity              | within $\pm 1$ Da of 663.43 Da                                                                                                                              | 663.43 Da (error 0 Da) <b>PASS</b>  |
| Purity                | Expected Purity $\geq 99.25$ area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31 | 99.99% <b>PASS</b>                  |
| Net Peptide Content   | every vial within $\pm 10\%$ of 500 mg                                                                                                                      | Vial A: 505.97 mg <b>PASS</b>       |
| Sterility · Rapid PCR | Rapid PCR screen                                                                                                                                            | Target DNA not detected <b>PASS</b> |

Layer Results

|                                                                                  |                         |                                                          |             |
|----------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------|-------------|
| 1 Identity                                                                       | LC-MS/MS (ESI+)         | 663.43 Da [M+H] <sup>+</sup><br>+/- 1 Da (theor. 663.43) | <b>PASS</b> |
| Identity confirmed: NAD+                                                         |                         |                                                          |             |
| Theoretical [M+H] <sup>+</sup>                                                   | 663.43 Da               | Observed [M+H] <sup>+</sup>                              | 663.43 Da   |
| Mass Error                                                                       | 0 Da (limit $\pm 1$ Da) | Mass error (ppm)                                         | 0 ppm       |
| Mass basis                                                                       | average                 |                                                          |             |
| Observed mass matches the theoretical mass within tolerance; identity confirmed. |                         |                                                          |             |



2

### Purity

HILIC-CAD homogeneity (universal detection)

Expected Purity  $\geq$  99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31

1 physical-vial purity observation

PASS

Expected Purity  $\geq$  99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31

| Vial   | Purity | Status |
|--------|--------|--------|
| Vial A | 99.99% | PASS   |

3

### Net Peptide Content

Quantitative HPLC vs reference std

505.97 mg  
each within +/- 10% of 500 mg

PASS

| Vial   | Measured  | Status |
|--------|-----------|--------|
| Vial A | 505.97 mg | PASS   |

4

### Sterility

Rapid Microbial DNA Screen — Qualification-Bound Target Panel

Sterility · Rapid PCR: No Growth

No microbial growth or target DNA detected

PASS

#### Sterility · Rapid PCR

Result

No Growth

Specification

Rapid PCR screen

PASS

## Reporting Scope & Limitations

**[Purity]** The chromatographic trace was not retained for this certificate. The purity value and its acceptance limit are unaffected.

**[Identity]** The mass spectrum was not retained for this certificate. Identity is reported from the recorded accurate mass against its theoretical value.

**[Sterility · Rapid PCR]** DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

## Digital Signatures

|                     |                |                    |                                     |
|---------------------|----------------|--------------------|-------------------------------------|
| Analyst             | Alana Reeves   | Analyst Signature  | ed25519:d752183076d0fa316a7a15cf... |
| Technical Reviewer  | Michael Niles  | Reviewer Signature | ed25519:e15e3daee7ee5eb7198b1f4e... |
| Laboratory Director | Daniel Brennan | Director Signature | ed25519:317fa14ef22cc1b1844fa88c... |

Physical instrument analysis is performed at Axiom Analytics' discretion (based on method, capacity, and order volume), either in Axiom's own laboratory under its documented quality system or by an independent partner laboratory engaged under confidentiality. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: samples are analyzed under double-blind conditions, identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at <https://axiomanalyticslab.com/verify/AX-2026-3703-7BKB>.

#### ✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 6fb516b90f1bd3b94515e4e2c6fa8edfd28f9ddeb3d0c16318c1fac28b156419...

Seal: ed25519:40e47df567f78281cdd165a707ce27903f6243c0...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.



**Axiom**  
ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL



**Axiom Analytics Laboratories**  
2108 N St Ste N, Sacramento, CA 95816 US

**AX-2026-3703-7BKB**

NAD+ · Lot 926-ND-500

Issued Sep 6, 2026 · v1

Verify: 7F4C-BD82-82F1



SCAN TO VERIFY

**RESEARCH USE ONLY.** All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

